Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Adrenoleukodystrophy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Adrenoleukodystrophy - Pipeline ...
Dublin, April 17, 2024 (GLOBE NEWSWIRE) -- The "Cerebral Adrenoleukodystrophy - Pipeline Insight, 2024" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights ...
Cerebral adrenoleukodystrophy (CALD) is a rare progressive, genetic brain disease that primarily presents in young boys, causing loss of neurological function and ultimately leading to early death.
Dublin, July 11, 2025 (GLOBE NEWSWIRE) -- The "Adrenoleukodystrophy Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...
The FDA has granted a Breakthrough Therapy designation to bluebird bio, Inc’s Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy, an X-linked ...
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with ...
(MENAFN- GlobeNewsWire - Nasdaq) The global adrenoleukodystrophy market is in a growth stage, driven by advancements in gene and drug therapies, improved diagnostic capabilities like newborn screening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results